Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/126808
DC FieldValue
dc.titleEighteen-month clinical safety and efficacy outcomes of sirolimus-, paclitaxel-and zotarolimus-drug eluting stents in diabetic patients undergoing percutaneous coronary intervention for complex coronary artery stenosis
dc.contributor.authorChong, E.
dc.contributor.authorPoh, K.K.
dc.contributor.authorLiang, S.
dc.contributor.authorHou, X.M.
dc.contributor.authorTan, H.C.
dc.date.accessioned2016-09-06T08:41:34Z
dc.date.available2016-09-06T08:41:34Z
dc.date.issued2010-05
dc.identifier.issn03044602
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/126808
dc.description.abstractIntroduction: This was a single centre registry study on clinical efficacy and safety of drug-eluting stent (DES) in diabetic patients undergoing percutaneous coronary intervention (PCI) for complex coronary lesions. Materials and Methods: A total of 288 diabetic patients who underwent elective PCI between September 2003 and June 2006 in our centre were enrolled and followed-up for 18 months. Among them, 79 (27.4%) patients received sirolimus-eluting stent (SES), 138 (47.9%) paclitaxel-eluting stent (PES) and 71 (24.7%) zotarolimus-eluting stent (ZES). The endpoints were major adverse cardiac events (MACE) and stent thrombosis rates. Results: Baseline demographics were comparable among the 3 DES groups (median age was 60 years; 69% men). Complex lesions (defined as ACC/AHA type C stenosis) accounted for 55.6% of the total lesions: SES (50.6%), PES (65.2%) and ZES (43.7%), P = 0.005. At 18 months follow-up, the composite endpoint of MACE was found in 12.7% in SES group, 8.7% in the PES group, 12.7% in ZES group and (P = 0.55). Stent thrombosis (ST) occurred in 1 patient (1.3%) in the SES group, 2 patients (1.4%) in PES group and 1 patient (1.4%) in ZES group, respectively (P = 1.00). Conclusion: The use of DES for elective PCI in diabetic patients was associated with favourable intermediate-term clinical outcomes with no significant differences in efficacy among the 3 groups. Stent thrombosis had low event occurrence rate.
dc.sourceScopus
dc.subjectDiabetes mellitus
dc.subjectDrug-eluting coronary stents
dc.subjectStent thrombosis
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.description.sourcetitleAnnals of the Academy of Medicine Singapore
dc.description.volume39
dc.description.issue5
dc.description.page381-384
dc.description.codenAAMSC
dc.identifier.isiutNOT_IN_WOS
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Page view(s)

63
checked on May 12, 2022

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.